About Atlantic Healthcare

Atlantic Healthcare plc is headquartered near Cambridge (UK) and operates across North America and Europe.

Our experienced Leadership Team has deep roots in the pharmaceutical industry and ambitious plans to develop and commercialize products that can improve the lives of patients, by providing clinicians with safe and effective treatments at cost-effective prices.

Working with key opinion leaders on our international Medical Advisory Board, we are currently developing differentiated, first-in-class treatments that leverage alicaforsen, an antisense therapeutic agent with a novel target for validated mechanism of action and the potential to treat multiple inflammatory GI diseases.

Our lead product candidate, CamligoTM (alicaforsen enema), is pending results of a Phase 3 clinical trial in orphan-designated IBD pouchitis. Our other programs are in localized topical delivery formulations of alicaforsen for the treatment of broader IBD indications.

With our recent acquisition of renzapride, we have expanded our clinical pipeline, providing the potential to address the unmet needs of patients with gastrointestinal motility disorders.

Our mission is to work collaboratively with healthcare providers in pursuit of treatments which improve the quality of life of patients with unmet medical needs and rare diseases.

Our vision is to be acknowledged as a leading specialist pharmaceutical company with a portfolio of therapeutics that meet the needs of patients, healthcare providers and the wider stakeholder community, while providing acceptable shareholder returns.

Our Team

Our experienced Leadership Team has deep roots in the pharmaceutical industry, with extensive experience developing, acquiring and commercializing products.

Find out more

Our Board offers a wealth of experience in growing successful pharmaceutical companies, having held leadership roles in large multi-national firms.

Find out more

Our international Medical Advisory Board comprises a group of eminent clinicians who provide expert advice and counsel to inform the development of our pipeline.

Find out more